Sending diagnostic samples to large reference laboratories for testing can leave patients waiting for days or weeks for answers.
This process is not fast enough.
Xzōm is providing near-patient diagnostic solutions, powered by their proprietary Alternating Current Electrokinetics (ACE) technology, that enable the isolation, analysis, and quantification of exosome biomarkers for early disease detection on a single platform from a minimal blood sample—with results in less than 30 minutes.
< 80 μL
Low Sample Volumes
30 Minutes
Rapid Results
1 Platform
Easy-to-Use Instrument
A Simple Workflow that Delivers Rapid Results
Xzōm’s easy-to-use, near-patient platform delivers rapid, high performance diagnostic results from small sample volumes.
At Xzōm, we utilize our patented Alternating Current Electrokinetics (ACE) technology to rapidly isolate exosomes, proteins, cell-free DNA, and other extracellular vesicles from a minimal blood sample.
Cells have a story to tell and exosomes are their messengers. Exosomes contain wide range of biomolecules – DNA, RNA, amino acids, proteins, and metabolites – that can indicate the onset of disease.
Exosomes arise from all cell types and are continuously secreted into all biological fluids—blood, saliva, urine, breast milk, amniotic fluid, cerebrospinal fluid, and they even cross the blood-brain-barrier—providing unlimited opportunities for biomarker analysis, early disease detection, and longitudinal monitoring of patient health.
Learn how we are leveraging exosomal data to detect multiple conditions.
The team at Xzōm is committed to delivering accessible, affordable, and accurate near-patient solutions for the detection of disease in its earliest stages, enabling faster intervention and improved outcomes.
Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform